Application of CK-666 in inhibiting ferroptosis and its drug preparation
By using CK-666 as an inhibitor of the actin-related protein Arp2/3 complex, it inhibits ferrodystrophy and prevents oxidative rupture of liposomes, solving the problem of insufficient stability and effectiveness of existing ferrodystrophy inhibitors in animals. The serum creatinine and urea nitrogen levels in ischemic reperfusion mice were significantly reduced, relieving renal tissue damage, and providing a new option for ferrodystrophy inhibitors.
Patent Information
- Application Number
- CN202211192576.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-09-28
AI Technical Summary
The stability and effectiveness of existing ferrodysfunction inhibitors in animals are insufficient, and the mechanism and effectiveness of CK-666 in mammals are unknown, and effective ferrodysfunction inhibitors are lacking in the treatment of related diseases.
As an inhibitor of the actin-related protein Arp2/3 complex, CK-666 stabilizes its inactive state by binding to the Arp2/3 complex, inhibits cell structure changes, has antioxidant ability, and can prevent oxidative rupture of liposomes. , thereby effectively suppressing iron death.
CK-666 significantly reduced serum creatinine and urea nitrogen levels in ischemic reperfusion mice, alleviated renal tissue damage, had better efficacy and safety, and was better than the known ferrodysfunction inhibitor Lip-1, providing New ferrodysmortality inhibitor options.
Smart Images

Figure CN115501225B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and more specifically, relates to the application of CK-666 in inhibiting ferroptosis and the preparation of medicines thereof. Background Art
[0002] Ferroptosis is a new type of cell-regulated death proposed in 2012. It is caused by the accumulation of iron-dependent lipid peroxidation. The accumulation of iron ions, the synthesis of polyunsaturated fatty acid lipids and the disorder of the cellular redox system are the key to inducing ferroptosis. Iron ions can oxidize lipids containing polyunsaturated fatty acids through the Fenton reaction or the action of lipid oxidase. The intracellular redox pathway, especially glutathione peroxidase 4 (GPX4), prevents cell ferroptosis by reducing lipid peroxidation. At present, more and more evidence shows that ferroptosis is involved in the occurrence of various diseases and is related to diseases caused by oxidative stress-related damage to various tissues and organs. Its mechanism is complex, such as neurodegenerative diseases, ischemia-reperfusion injury, acute liver and kidney damage, etc. Ferroptosis can also be induced by a variety of compounds, such as erastin or clinical drugs sorafenib, which can induce cell-triggered ferroptosis. Therefore, clinically, inhibiting ferroptosis can not only effectively alleviate ferroptosis-related diseases, but also reduce the side effects of drugs. The development of drugs related to efficient ferroptosis inhibitors will bring unprecedented opportunities for the treatment of ferroptosis-related diseases.
[0003] However, the currently known ferroptosis inhibitors are mainly used for cell experiments in vitro, but their stability and effectiveness in animals are insufficient. Typical ferroptosis inhibitors such as Ferrostatin-1 (Fer-1) can inhibit ferroptosis of HT-1080 cells induced by RSL3 or Erastin, but Fer-1 is metabolically unstable in the body and the inhibitory effect is poor. Although the ferroptosis inhibitor Liproxstatin-1 (Lip-1) has stronger stability, its safety and effectiveness are still far from the clinical application standards. Therefore, the screening and development of ferroptosis inhibitors has become one of the hot spots and difficulties in the field of ferroptosis research.
[0004] CK-666 is an inhibitor of the actin-related protein Arp2 / 3 complex. It stabilizes the inactive state by binding to the Arp2 / 3 complex and is used to study Arp2 / 3-mediated changes in cell structure. The Arp2 / 3 complex is a protein containing 7 subunits that can nucleate microfilaments, inhibit the formation of lamellipodia, and affect cell migration and endocytosis. At present, CK-666 is mainly studied in lower organisms such as in vitro cells, yeast and insects, and there are few reports on related studies of CK-666 in mammals such as mice. The mechanism of action and effectiveness of CK-666 in mice are still unclear, and there is no research showing that CK-666 is related to the mechanism of ferroptosis. Therefore, it is of great significance to develop more ferroptosis inhibitors and drugs with better effects and better safety for the treatment of related diseases caused by ferroptosis. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the defects and shortcomings of the above-mentioned problems and provide the application of CK-666 in inhibiting ferroptosis and the preparation of its medicine.
[0006] The purpose of the present invention is to provide a new application of CK-666 in inhibiting ferroptosis and preparing a drug for inhibiting cell ferroptosis.
[0007] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0008] The present invention shows that CK-666 can effectively inhibit ferroptosis induced by various methods, and CK-666 also has good antioxidant capacity, which can prevent the oxidation and rupture of liposomes, indicating that CK-666 can inhibit ferroptosis by reducing cell lipid peroxidation. At the same time, CK-666 can significantly reduce the levels of blood creatinine and urea nitrogen in ischemia-reperfusion mice, and can significantly alleviate renal tissue damage when used in ischemia-reperfusion mice, with better effectiveness.
[0009] Therefore, the present invention provides the use of CK-666 in inhibiting ferroptosis, in preparing a ferroptosis inhibitor, as a ferroptosis inhibitor, in preparing a drug for inhibiting cell ferroptosis, and in preparing a drug for treating a disease caused by ferroptosis.
[0010] CK-666 used in the present invention is a cell permeability inhibitor of actin-related protein Arp2 / 3 complex, and its chemical formula is C 18 H 17 FN2O, the structural formula is shown in the following formula (I):
[0011]
[0012] Preferably, CK-666 is used as a ferroptosis inhibitor in the preparation of a drug for treating a disease caused by ferroptosis.
[0013] In particular, CK-666 provided by the present invention can be used as a ferroptosis inhibitor or in the preparation of drugs for treating ferroptosis and related diseases caused by ferroptosis, including but not limited to renal / liver / heart ischemia-reperfusion, neurodegenerative diseases or acute liver and kidney damage.
[0014] Preferably, the CK-666 is used to inhibit ferroptosis of cells and / or tissues and organs.
[0015] Preferably, the cells are fibrosarcoma cells, embryonic lung fibroblasts and / or mouse embryonic fibroblasts.
[0016] Preferably, the medicament contains a pharmaceutically acceptable carrier or excipient.
[0017] The present invention has the following beneficial effects:
[0018] The present invention provides an application of CK-666 in inhibiting cell ferroptosis and the preparation of a drug thereof. Studies have shown that the Arp2 / 3 complex inhibitor CK-666 can effectively inhibit ferroptosis induced by various methods, can significantly rescue ferroptosis induced by RSL3 and Erastin, and Pfa1 cell ferroptosis caused by Gpx4 gene knockout, and as the concentration of CK-666 increases, the cell ferroptosis inhibition effect is better; and CK-666 also has good antioxidant capacity and can prevent the oxidative rupture of liposomes, indicating that CK-666 can inhibit ferroptosis by reducing cell lipid peroxidation.
[0019] At the same time, CK-666 can significantly reduce the levels of blood creatinine and urea nitrogen in ischemia-reperfusion mice, and can significantly alleviate renal tissue damage in ischemia-reperfusion mice, and can be used to prepare drugs for treating diseases caused by ferroptosis. The CK-666 provided by the present invention can be used as a ferroptosis inhibitor, and its effect is better than Lip-1, with better antioxidant properties and safety, providing a new option for the research and development of efficient ferroptosis inhibitor-related drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Results of cell ferroptosis detection induced by different methods (a. RSL3 induces ferroptosis of HT1080 cells; b. Inhibition rate of ferroptosis at different CK-666 concentrations under RSL3 induction; c. Erastin induces HT1080 cells; d. RSL3 induces ferroptosis of 293T cells; e. Pfa1 cell ferroptosis caused by Gpx4 gene knockout);
[0021] Figure 2 The results of in vitro antioxidant capacity (a) and inhibition of liposome oxidative rupture (b) are shown;
[0022] Figure 3 The figures are the results of renal ischemia-reperfusion injury (a. creatinine level in mouse serum; b. urea nitrogen level in mouse serum; cH&E staining of renal tubule area). DETAILED DESCRIPTION
[0023] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0024] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0025] The sources of materials used in the following examples are as follows: human fibrosarcoma cells HT1080 and human embryonic lung fibroblasts 293T were purchased from China Center for Type Species Collection (CTCC); immortalized mouse embryonic fibroblasts pfa1 with inducible GPX4 knockout were donated to the research group of Professor He Rongrong of Jinan University; male 8-12 week old C57 mice were purchased from Beijing Huafukang Biotechnology Co., Ltd.
[0026] Example 1 Effect of CK-666 on cell ferroptosis
[0027] In this example, two inducers of cell ferroptosis, glutathione peroxidase 4 (GPX4) inhibitors RSL3 and Erastin, were used to induce cell ferroptosis, and then different concentrations of CK-666 inhibitors were added for treatment. At the same time, a control group (ctl group) without CK-666 inhibitor was set to detect cell survival rate.
[0028] Human fibrosarcoma cells HT1080 and human embryonic lung fibroblasts 293T were inoculated at 4000 cells / 100 μL / well in a 96-well cell culture plate. After the cells adhered to the wall for 12-24 hours, the cells were added to 100 μL of culture medium containing corresponding concentrations of RSL3 (0, 4nM, 8nM, 16nM, 31nM, 125nM, 500nM, 2000nM) or erastin (0, 0.15μM, 0.3μM, 0.6μM, 1.25μM, 2.5μM, 5μM, 10μM) and different concentrations of CK-666 inhibitor (0, 6μM, 12.5μM, 25μM, 50μM, 100μM). Three replicate wells were set for each drug concentration. After 24 hours of treatment, the nucleic acid dyes Hoechst and propidium iodide (PI) were added for staining for 15 minutes. Hoechst can penetrate the cell membrane and stain the nuclei of all cells. PI cannot penetrate the complete cell membrane and can only stain dead cells. Therefore, Hoechst and PI stain the total cells and dead cells in different colors respectively. Then, the high-throughput confocal imaging system was used to take pictures and count the cell death rate.
[0029] Since Gpx4 gene knockout can also cause ferroptosis of Pfa1 cells, the ferroptosis of Pfa1 cells caused by Gpx4 gene knockout was also measured. The cells were prepared according to the above method, and then 100 μL of culture medium containing 1 μM 4-OHT and 100 μM CK-666 was added. After treatment for 72 hours, the cell activity was detected using the same method.
[0030] The results are as follows Figure 1 As shown, in HT1080 cells, the ferroptosis inducer RSL3 ( Figure 1 a) and Erastin( Figure 1 c) As the concentration increases, the survival rate of cells will also decrease. After adding CK-666, the ferroptosis induced by RSL3 and Erastin can be significantly rescued. Moreover, as the concentration of CK-666 increases, the ferroptosis induced by RSL3 is inhibited more ( Figure 1 b). At the same time, RSL3-induced ferroptosis in 293T cells can also be significantly inhibited by CK-666 ( Figure 1 d). In addition, ferroptosis of Pfa1 cells caused by Gpx4 gene knockout can also be significantly inhibited by CK-666 ( Figure 1 e). These results indicate that CK-666 can effectively inhibit ferroptosis induced by various cell types.
[0031] Example 2 In vitro antioxidant capacity of CK-666
[0032] 1. DPPH free radical determination
[0033] The DPPH free radical has a single electron, and its alcohol solution is purple and has strong absorption at 515nm. When an antioxidant is present, the DPPH free radical is scavenged, the color of its solution becomes lighter, the absorbance at 515nm decreases, and within a certain range, the change in its absorbance is proportional to the degree of free radical scavenging. Therefore, the change in absorbance can be detected by an ELISA instrument to reflect the free radical scavenging situation. The in vitro antioxidant capacity of CK-666 was detected using a DPPH assay kit. The specific operation process was performed according to the method provided on the kit, in which different concentrations of vitamin C (3μM, 12.5μM, 50μM) were used as positive controls, and ferroptosis inhibitors Fer-1 and Lip-1 were used for treatment.
[0034] 2. Effect of CK-666 on liposome oxidative rupture
[0035] Terbium ions are encapsulated by phospholipid molecules to form liposomes. 2+ Under the action of HCl and H2O2, the liposomes gradually oxidize and rupture, releasing terbium ions. The rupture of the liposomes can be reflected by detecting the change in fluorescence value using an ELISA instrument, as terbium ions can react with dipicolinic acid (DPA) to emit fluorescence.
[0036] Dissolve 2 mg of soybean lecithin in 500 μL of chloroform and blow dry with nitrogen in a small round-bottom flask to form a uniform plasma membrane at the bottom of the flask. Add 1 mL of buffer TL (20 mM HEPES pH = 7.4, 0.1 M sodium chloride, 50 mM sodium citrate, 15 mM terbium chloride) to resuspend the plasma membrane obtained in the previous step, and then prepare liposomes using a mini-extruder according to the instructions.
[0037] Wash by centrifugation through a 100KD cut-off ultrafiltration tube to remove unencapsulated terbium ions in the liquid. After the last centrifugation, resuspend with 500μL buffer L (20mM HEPES pH=7.4, 0.1M sodium chloride). Mix 5μL liposome with 10μM H2O2, 50μM FeSO4, 1μM Lip-1 or 100μM CK-666, and add buffer L to a total volume of 100μL. Set the microplate reader to 270nm excitation light and 490nm emission light to detect and record the fluorescence signal every 60s. After 3 hours, add 0.1% Triton X-100 to break all liposomes, and detect the fluorescence signal 10 times at the same time. All changes in fluorescence intensity signals obtained are statistically analyzed.
[0038] 3. Results
[0039] The results of the in vitro antioxidant capacity of CK-666 are as follows Figure 2 As shown in a, CK-666 has a certain in vitro antioxidant capacity, and its antioxidant activity is better than that of the 12.5 μM vitamin positive control. Its antioxidant capacity is between the known ferroptosis inhibitors Lip-1 and Fer-1, but is significantly better than Lip-1.
[0040] The results of CK-666 inhibition of liposome oxidative rupture are as follows Figure 2 As shown in b, Fe 2+ and H2O2 can cause liposomes to oxidatively rupture, while the addition of CK-666 can prevent the oxidative rupture of liposomes, and its effect is equivalent to that after using the ferroptosis inhibitor Lip-1.
[0041] Taken together, these results indicate that CK-666 can inhibit ferroptosis by reducing cellular lipid peroxidation.
[0042] Example 3 Effect of CK-666 on renal ischemia-reperfusion injury
[0043] 48 male C57BL / 6J mice aged 8-12 weeks were selected and randomly divided into 4 groups for experiments, which were set as sham operation group (Sham) (blank control), modeling group (IRI+DMSO) (ischemia reperfusion group, i.e. positive control), ferroptosis inhibitor Lip-1 treatment group (IRI+Lip-1) (negative control), CK-666 treatment group (IRI+CK-666) (experimental group). Two days before surgery, mice were intravenously injected with 200μLDMSO or 10mg / kg Lip-1 or 30mg / kg CK-666 every day, and mice were fasted for 12h before surgery. During surgery, mice were anesthetized with 3% sodium pentobarbital, and the skin and muscles were cut at 0.5cm beside the back spine and 0.5cm below the ribs to see the kidneys, and the renal arteries of both kidneys were carefully separated. At the same time, the renal arteries on both sides were quickly clamped with artery clamps. The artery clamps were released after 30min, blood flow was restored, and the openings were sutured. After 24 hours, the mice were killed and serum and kidneys were collected. The serum was sent to a testing company to test the levels of blood creatinine and urea nitrogen to evaluate kidney function. At the same time, the kidneys were stained with H&E.
[0044] The results are as follows Figure 3 As shown in Figure 2, the levels of serum creatinine and urea nitrogen in mice in the ischemia-reperfusion model group (IRI+DMSO) increased significantly ( Figure 3 ab), H&E staining results also showed obvious tubular damage such as vacuolar degeneration in the renal tubule area ( Figure 3c), indicating that kidney function is damaged. After the mice with ischemia-reperfusion were treated with the ferroptosis inhibitor Lip-1 (IRI+Lip-1), the blood creatinine value of the mice decreased, and the renal tubular damage was alleviated to a certain extent, but the change in serum urea nitrogen was not significant enough. Treatment with CK-666 can significantly reduce the levels of blood creatinine and urea nitrogen in mice with ischemia-reperfusion. The results of H&E staining also showed that after CK-666 treatment, the renal tubular casts disappeared, the necrosis and shedding of epithelial cells, and the vacuolar degeneration were reduced, indicating that the renal tissue damage was significantly alleviated ( Figure 3 c) These results indicate that CK-666 can effectively alleviate renal ischemia-reperfusion injury in mice, and its effect is better than that of ferroptosis inhibitor Lip-1.
[0045] Based on the above results, it can be seen that CK-666 can effectively inhibit cell ferroptosis and ferroptosis-related diseases in mice (renal ischemia-reperfusion injury), and can be used to prepare anti-ferroptosis drugs.
[0046] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Application of CK-666 in the preparation of drugs for treating diseases caused by ferroptosis; It is characterized in that The structural formula of CK-666 is The disease is renal ischemia-reperfusion injury.
2. The use according to claim 1, It is characterized in that The medicine contains a pharmaceutically acceptable carrier or excipient.
